Literature DB >> 11454991

Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines.

F Timeus1, E Ricotti, N Crescenzio, E Garelli, A Doria, M Spinelli, U Ramenghi, G Basso.   

Abstract

Flt-3 ligand (FL) is a cytokine that promotes the survival, proliferation, and differentiation of hematopoietic progenitors in synergy with other growth factors, such as stem cell factor. Previously we have demonstrated that stem cell factor and its receptor c-kit are expressed in neural crest-derived tumor cells and that a c-kit block induces their apoptosis. Here we have evaluated the expression of flt-3 and its ligand in 12 neuroectodermal tumor cell lines from neuroblastoma (NB), neuroepithelioma (NE), Ewing sarcoma (ES), and peripheral neuroectodermal tumor (PNET) and in 38 biopsies: 19 from NB and 19 from ES and PNET. RT-PCR demonstrated the expression of flt-3 and FL in all lines. Coexpression was observed in 42% of NB and in 74% of ES and PNET biopsies. Flow cytometry confirmed the presence of membrane and cytoplasmic flt-3 and membrane FL in all lines, whereas soluble FL protein was not measurable in their supernatants. Microphysiometric demonstration of acidification of the medium provided evidence of the specific response of cell lines to FL stimulation. Specific flt-3 phosphorylation after FL treatment was also demonstrated by Western blotting analysis. In cells growing in RPMI plus 1% fetal calf serum, FL revealed a significant proliferating activity, more evident in NB and NE lines (mean increase of viable cells, 73 +/- 26% after 1 day). Treatment with flt-3 antisense oligonucleotides significantly inhibited cell growth. FL also displayed an antiapoptotic activity: after a 12-hour culture in the presence of 0.1% fetal calf serum, FL caused a 50% reduction of apoptotic cells. These results provide further evidence that neuroectodermal and hematopoietic cells share common regulatory pathways, and could be of interest in the clinical management of neuroectodermal tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454991     DOI: 10.1038/labinvest.3780314

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

Review 1.  Granulocyte Colony-Stimulating Factor (G-CSF) for the Treatment of Spinal Cord Injury.

Authors:  MirHojjat Khorasanizadeh; Mahsa Eskian; Alexander R Vaccaro; Vafa Rahimi-Movaghar
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

Review 2.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

3.  Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.

Authors:  Kenneth B Fallon; Necat Havlioglu; Leo H Hamilton; Tammy P H Cheng; Steven L Carroll
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

4.  Targeting angiogenesis for controlling neuroblastoma.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  J Oncol       Date:  2011-08-25       Impact factor: 4.375

5.  Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI.

Authors:  Mikko O Laukkanen; Francesca Cammarota; Tiziana Esposito; Marco Salvatore; Maria D Castellone
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.